The Room

On December 10, 2025, thirteen people sat in a room and evaluated a medical construct. Six months later, their evaluation became federal policy.

Every individual change they recommended is evidence-based. Every change addresses a real problem. None of it is wrong.

The question is what was never asked.

The Thirteen

Name	Specialty	Note
Helen L. Bernie, DO, MPH	Andrology
ADM Brian Christine, MD	Urology (penile implants)	Now HHS Assistant Secretary for Health
MAJ Theodore Crisostomo-Wynne, MD	Military medicine
Michael C. Davis, MD, PhD	Men's health
Richard Iorio, MD	Men's health
Mohit Khera, MD, MBA, MPH	Urology	TRAVERSE author. Co-moderated the panel.
Tobias S. Köhler, MD, MPH, FACS	Urology (men's health)	Mayo Clinic
Larry Lipshultz, MD	Urology (male reproduction)	Baylor
Martin Miner, MD	Men's health	Brown
Abraham Morgentaler, MD, FACS	Urology (sexual medicine)	Originated the saturation model
John P. Mulhall, MD, MSc	Sexual medicine	MSKCC
Shalin Shah	Industry	CEO, Marius Pharmaceuticals (testosterone company)
Landon Trost, MD	Urology (male infertility)

Count the endocrinologists. Count the internists. Count the epidemiologists. Count the bone specialists.

This was a panel about endocrine labeling. Every member either practices men's health urology, researches testosterone therapy, or sells it.

What They Said

Khera, who co-authored the TRAVERSE trial — the study whose cardiovascular noninferiority finding is the primary evidence basis for the labeling changes — also co-moderated the panel. He argued that 85% of patients currently receiving TRT would be considered off-label under the existing label. The label, in this framing, was wrong about the patients.

Shah, CEO of Marius Pharmaceuticals, pitched fast-track approval for testosterone in combination with GLP-1 drugs as "a multibillion dollar preventive care opportunity."

Gary Schwitzer and the PharmedOut project at Georgetown documented the disclosure landscape: two speakers claiming "no relevant disclosures" had documented consulting relationships with at least twelve and six testosterone product manufacturers, respectively. Schwitzer characterized the proceedings as "self-congratulatory hyperbole" and noted that the panel "claimed testosterone prevents cardiovascular disease and diabetes despite lacking supporting evidence."

Public Citizen raised process concerns: the panel's co-moderator authored the pivotal trial being discussed, panelists appeared selected to support predetermined conclusions, and the proceedings should have been referred to the formal Drug Safety and Risk Management Advisory Committee or the Endocrinologic and Metabolic Drugs Advisory Committee under FACA compliance. The National Center for Health Research observed that the panel "focused on opinions, not solid scientific evidence" and "did not adequately mention risks."

What They Didn't Say

Nobody in the room asked how to distinguish the man whose testosterone is low because obesity is suppressing his hypothalamic signaling from the man whose testosterone is low because his axis is genuinely insufficient.

Nobody raised the question of 426% inter-laboratory variability. Nobody mentioned that thirteen clinical guidelines define hypogonadism using thirteen different diagnostic criteria. Nobody noted that 30% of men who test low will normalize on retest without any intervention.

Nobody asked what happens downstream. If the label no longer distinguishes "age-related" from other causes, but the underlying diagnostic infrastructure still can't reliably identify who has what, you've opened a gate to an unmapped territory.

These aren't esoteric academic questions. They are the measurement chaos that drives the 3.3% guideline-concordant prescribing rate that Pederson et al. documented. If only 3.3% of current prescribing meets any single guideline's criteria, removing the label barrier doesn't fix the prescribing problem. It changes the legal terrain without changing the clinical map.

The Timeline

From panel to policy in six months. The manufacturers didn't need to file anything. HHS acted unilaterally.

The Person

ADM Brian Christine is a urologist who specializes in penile implant surgery. In November 2025, he was confirmed as HHS Assistant Secretary for Health — the senior public health official in the federal government. In December 2025, in that capacity, he convened the Expert Panel on TRT. By May 2026, he had been promoted to Deputy Secretary of HHS, the department's second-ranking position.

The number two official at the Department of Health and Human Services is a men's health urologist. The labeling changes came from his agency, under his authority, following a panel he convened, staffed entirely by his clinical community.

This is not a conflict of interest in the narrow sense. Christine disclosed his background. His expertise is real. But it is a structural alignment: the community that defined the construct of "testosterone deficiency" was also the community that evaluated it, and a member of that community held the institutional authority to act on the evaluation.

The Signal from Outside

The Endocrine Society was not in the room. But they sent two signals simultaneously.

Signal one: In February 2026, they submitted formal comments to the FDA supporting TRT for symptomatic men "regardless of cause" — aligning with the panel's direction. They support the label change.

Signal two: At ENDO 2026, running concurrently with the June 18 announcement, they released the Papaleontiou study: 200 male patients at Michigan Medicine, 12% guideline-concordant prescribing. Fifty-five percent had unaddressed obstructive sleep apnea. Sixty-three percent were obese. Forty-five percent of prescriptions came from primary care.

Twelve percent. Not 3.3% — a different methodology, different institution, same finding at a different scale. Even by the most generous assessment, at least 88% of current testosterone prescribing doesn't meet the clinical guidelines that the prescribers' own professional society wrote.

The timing is not coincidental. The Endocrine Society is saying two things at once: Yes, modernize the label. And know that 88% of prescribing already ignores our guidelines, before you made access easier.

This is not opposition. It is ambivalence so precisely calibrated that it amounts to a prediction.

What's Unchanged

The label changed. The construct didn't.

"Testosterone deficiency" still refers to a single lab value — total testosterone below a threshold — that contains at least two non-overlapping populations requiring opposite interventions. The man whose hypothalamus is suppressed by metabolic inflammation needs metabolic restoration. The man whose axis is genuinely insufficient needs hormone replacement. They present identically on a morning blood draw.

Thirteen clinical guidelines still disagree on the threshold. The inter-laboratory variability hasn't changed. HoSt-TT has certified one testosterone assay platform in fifteen years of effort. No screening tool exists that a primary care physician can use to distinguish the populations. The 12% guideline concordance rate reflects a system in which the instrument, the construct, and the clinical pathway are all broken, and the label was one of several barriers that at least forced a moment of friction.

That friction is now gone.

I am not arguing it should have stayed. The evidence supports these changes. TRAVERSE demonstrated cardiovascular noninferiority. Morgentaler's saturation model has dismantled the prostate cancer fear. The 2015 limitation of use was always awkward — it said safety and effectiveness were "not established" for a condition that most prescribing targeted.

But the panel that evaluated the construct was the same community that built it. They answered the questions they had been asking for decades — Is TRT safe? Does the label reflect the evidence? — and they answered correctly. The questions they didn't ask — What is this construct actually measuring? Who are these patients? How do we tell them apart? — are the ones that matter now.

The gate is open. The map doesn't exist.